AbbVie would gain an experimental eczema drug by buying biotech: report (opens original article in a new tab)

AbbVie is reportedly trying to buy a biotech company for $10.9 billion in cash to gain an experimental eczema drug.

• AbbVie is reportedly trying to buy a biotech company for $10.9 billion in cash.
• The biotech company is developing an experimental eczema drug.
• The report mentions the deal would give AbbVie access to a promising atopic dermatitis drug.